Latest Breaking News On - Digital pharma - Page 6 : comparemela.com

Seven European countries clamp down on AstraZeneca COVID-19 vaccine as safety worries threaten rollout

AstraZeneca’s COVID-19 vaccine rollout has gotten off to a rocky start in Europe. First, a supply shortfall triggered a public back-and-forth between executives and government officials. Then, several countries raised efficacy doubts for people over 65. Now some countries are raising safety concerns.

Angela merkelPharma europeEuropean medicines agencyEuropean centre for disease preventionPharma marketingDigital pharmaFrench president emmanuel macronEuropean centreDisease preventionEuropean commissionCovid 19Preventive vaccinesஏஞ்சலா மர்கல்பார்மா யூரோப்ஐரோப்பிய மையம் க்கு நோய் ப்ரெவெந்ஶந்பார்மா சந்தைப்படுத்தல்

Johnson & Johnson to sell another 100M coronavirus vaccine doses to U S , taking America s supply to 800M doses: reports

Mar 10, 2021 10:24am Johnson & Johnson will sell another 100 million COVID-19 vaccine doses to the U.S., according to reports.(J&J) One year ago this week, the COVID-19 pandemic hit home with Americans when Tom Hanks revealed he had tested positive and the NBA postponed its season indefinitely. Things have changed mightily since then: A national vaccine rollout is gaining steam, and the U.S. is inking yet another huge supply deal. The Biden administration is purchasing another 100 million doses of the one-dose shot from Johnson & Johnson, according to media reports. The vaccine is just rolling out across the U.S. after an FDA authorization late last month.

United statesJustin trudeauTom hanksPharma europeJoe bidenMerck coPharma marketingDigital pharmaJohnson ampJoseph bidenMerck amp coCovid 19ஒன்றுபட்டது மாநிலங்களில்ஜஸ்டின் திருடேௌஉடோம் ஹாங்க்ஸ்பார்மா யூரோப்

PatientPoint merges with Outcome Health, combining networks and sunsetting the scandal-tainted Outcome brand

Mar 10, 2021 9:35am PatientPoint and Outcome Health are merging to form the new PatientPoint point-of-care network and company. (Alpha Stock Image) After enduring a turbulent few years, point-of-care advertising and marketing company Outcome Health is getting a makeover, thanks to a merger. PatientPoint is merging with Outcome to create PatientPoint Health Technologies point-of-care network, and in the process it s retiring the Outcome name. The combined company will be led by PatientPoint executives and CEO Mike Collette. Outcome Health CEO Matt McNally and chief operating officer Nandini Ramani are leaving the company. The denouement of the Outcome Health brand is not entirely surprising, as it brings to an end a saga that included allegations of self-dealing, audits, an investor lawsuit and more.

United statesMatt mcnallyMike colletteShradha agarwalPharma europeNandini ramaniPatientpoint health technologiesCannes lions healthOutcome healthPharma marketingDigital pharmaChicago businessWall street journalPoint of careஒன்றுபட்டது மாநிலங்களில்மேட் ம்க்நல்லி

Bayer unveils first look at its post-Xarelto, post-Eylea life—and it s better than expected

Bayer unveils first look at its post-Xarelto, post-Eylea life—and it s better than expected
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

Stefan oelrichPharma europePharma marketingDigital pharmaWall streetபார்மா யூரோப்பார்மா சந்தைப்படுத்தல்டிஜிட்டல் பார்மாசுவர் தெரு

NantKwest starts dosing in subcutaneous, sublingual and oral COVID-19 vaccine trials

Patrick Soon-Shiong, M.D., executive chairman of ImmunityBio and NantKwest (NantKwest) ImmunityBio and NantKwest have begun dosing participants with subcutaneous, sublingual and oral COVID-19 vaccine candidates. The trials are designed to determine which combination of routes of administration holds the most potential. While a clutch of COVID-19 vaccines are now in commercial use around the world, the potential for the coronavirus to become a pathogen that continues to circulate for years means there may be a long-term opportunity for prophylactics. ImmunityBio and NantKwest are part of a group of vaccine developers working to seize that opportunity. The partners recently took a step forward when dosing began in clinical trials in the U.S. and South Africa. Two U.S. phase 1b clinical trials are evaluating the effect of giving sublingual or oral vaccines in addition to a subcutaneous formulation. Six subjects have been dosed in each U.S. trial.

South africaSouth africanPharma europePharma marketingDigital pharmaPatrick soon shiongCorona virusCovid 19Oral vaccinesSubcutaneous drug deliveryDrug deliveryபார்மா யூரோப்பார்மா சந்தைப்படுத்தல்டிஜிட்டல் பார்மாகொரோனா வைரஸ்வாய்வழி தடுப்பு மருந்துகள்